



C. Richard Conti, MD, MACC, FESC, Palm
Beach Heart Association Eminent Scholar
(Cardiology Professor of Medicine)
Gainesville, Florida
Enhanced External Counterpulsation (EECP) is an emerg-
ing nonpharmacologic outpatient therapy for patients with
angina pectoris. In simplest terms, EECP involves sequen-
tial inflation and deflation of compressive cuffs wrapped
around the patient’s calves, lower thighs and upper thighs.
These events are timed to the cardiac cycle via ECG signals.
During diastole cuffs inflate sequentially from the calves
proximally to raise diastolic aortic pressure and theoretically
increase coronary perfusion pressure. At the same time,
venous return is increased, which theoretically should in-
crease cardiac output by the Starling mechanism. The cuffs
are then rapidly decompressed at the onset of systole. This
rapid drop in diastolic pressure significantly unloads the left
ventricle, thus allowing the work of the ventricle to be
decreased.
See page 1833
This combination of events results in a decrease of
myocardial oxygen demand and an increase in coronary
blood flow, a combination beneficial for the therapy of
patients with the symptoms related to myocardial ischemia.
It is also possible that EECP may relieve symptoms by
facilitating the development or opening of coronary collat-
erals, as has been reported with the use of intra-aortic
balloon counterpulsation (1). However, as far as I can tell,
angiographic studies have not been published evaluating
coronary collateral blood flow or change in TIMI antegrade
flow in these patients.
I have a particular interest in this form of therapy of
angina pectoris because I worked with David Goldfarb and
Greg Brown on counterpulsation experiments in dogs in
1965 (2). We used a cannula inserted into the femoral artery
in which blood was withdrawn and returned to the arterial
system with a pumping device timed in systole and diastole.
A few years later, the intraaortic balloon pump was devised.
As everyone knows, this technique has survived the test of
time and is used commonly in patients with unstable
coronary syndromes, cardiogenic shock, high risk angio-
plasty and cardiac surgery.
Use of EECP has evolved. Lawson et al. (3) evaluated the
current device’s efficacy and tolerability in a group of
patients with chronic stable exertional angina pectoris.
Their results were quite encouraging and stimulated the
performance of the Multicenter Study of Enhanced Exter-
nal Counterpulsation (MUST-EECP) that is being re-
ported in this issue of the Journal of the American College of
Cardiology by Arora et al. (4). They reason that no con-
trolled trial had been conducted to determine whether the
procedure is effective and safe in reducing angina pectoris in
patients with coronary artery disease.
The MUST-EECP trial is a randomized, placebo (sham)
controlled multicenter trial designed to evaluate EECP in
patient with angina and documented myocardial ischemia
and coronary artery disease.
This therapy is not for everyone, as Arora et al. (4) note.
There was a significant number of exclusions of patients. It
is worthwhile to repeat those exclusions here. They include
the following:
“MI or CABG in the preceding three months, cardiac
catheterization in preceding two weeks, unstable angina,
overt congestive heart failure or left ventricular ejection
fraction less than 30%, significant valvular disease, blood
pressure greater than 180/100 mm Hg, permanent pace-
maker or implantable defibrillator, nonbypassed left main
stenosis greater than 50%, severe symptomatic peripheral
vascular disease, varicosities, deep vein thrombosis, phlebitis
or stasis ulcer, bleeding diathesis or warfarin use with INR
greater than 2.0, atrial fibrillation or frequent ventricular
premature beats that would interfere with EECP triggering,
baseline ECG abnormalities that would interfere with
interpretation of exercise ECG, pregnant women or women
of childbearing potential and subjects unable to undergo
treadmill testing.” (4)
Patients in MUST-EECP underwent 35 h of either active
counterpulsation or inactive counterpulsation with sessions
lasting 1 h each. In the active counterpulsation group,
pressure applied to the cuffs was 300 mm Hg, and in the
control group, 75 mm Hg. The latter pressure application
preserved the appearance and feel of an EECP application
but was not sufficient to alter the patient’s blood pressure in
a measurable way.
The investigators were clever to prevent any opportunities
for study subjects in one group to discuss their experience
with patients in the other group. This was accomplished by
scheduling appointments in such a way as to minimize any
opportunity for study subjects in one group to meet with
other patients.
After the course of treatment, the treated group had a
significant prolongation of time to greater than 1 mm
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ST-segment depression compared with the inactive group,
but there was no significant difference in exercise duration
or angina counts either in the control or the treated group.
The investigators also report a relatively high incidence of
adverse events, more so in the active treated group than in
the inactive group.
Finally, the investigators also admit that it was impossible
to blind personnel applying the EECP treatment to the
patient. Thus, there was always the possibility that the
treating person might have suggested which form of treat-
ment the patient was receiving.
I believe that EECP has great potential and could be
particularly applicable to patients who are not candidates for
revascularization but who continue to have repetitive epi-
sodes of myocardial ischemia.
The principle of counterpulsation has always made great
sense to me because it increases diastolic pressure and thus
influences coronary perfusion. Systolic pressure may be
lowered in these patients because of a reflex arc related to
higher diastolic pressure and the rapid fall in diastolic
pressure just before systole unloads the ventricle and in-
creases cardiac output.
Arora et al. (4) and others have studied this technique
quite well, and it deserves consideration in patients who
continue to present difficult management problems. How-
ever, I do not believe this technique is first line therapy. We
still should aggressively optimize pharmacologic therapy or
revascularization.
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